Kate Adamala's lab built SpudCell — a fat bubble membrane carrying small rings of DNA — and filed it as a public benefit corporation before peer review, racing to lock in the term 'cell' as a commercial and scientific category before the field reaches consensus on whether the…
A University of Minnesota lab has built a small, self-assembling object out of the simplest pieces of life it can find. The object, a fat bubble about the size of a bacterium carrying a loop of DNA, divides and passes its DNA to new bubbles, with roughly 30 percent of the descendants still carrying the original genetic instructions after five generations (Biotic, the Adamala lab research page). The team calls it SpudCell and argues, in a set of institutional statements, that it is the first cell-like system whose every molecular piece is known and supplied from the bench (University of Minnesota news release).
What it is not, says Kate Adamala, the associate professor leading the work, is a finished living cell. "It's a cell-like system," she told reporters, drawing the line between a system that exhibits some properties of life and a cell that runs on its own (STAT News coverage). That careful phrasing is now at the heart of a definitional fight that may matter far beyond Minnesota.
SpudCell, in plain terms, is a liposome, a tiny sphere of fatty molecules that mimics a cell membrane, stuffed with plasmids, the small rings of DNA that bacteria use to swap genes. Left in the right broth, the liposome grows, pinches into two, and the new copies inherit the plasmids at a rate of roughly 30 percent after five rounds of division, according to the team's figures (Quanta Magazine explainer). That is a measurable kind of heredity, but a partial one: most of the grandchildren are empty.
The system is also not self-sufficient. It has to be fed both nutrients and a key enzyme, and the food itself has to be packaged in additional liposomes before the construct can use it, a structural reminder that the bubbles cannot harvest energy from their environment on their own (Quanta Magazine). For some synthetic biologists, those caveats make "cell-like" the right word and "alive" the wrong one. The field has been here before. The 2010 Synthia bacterium, built by Craig Venter's team, and the JCVI minimal cell, a stripped-down microbe with the smallest known genome, both drew similar claims of "first synthetic life" and both drew pushback that "life" should be reserved for objects that sustain themselves without laboratory feeding (Science magazine analysis).
What makes SpudCell's roll-out different is the speed at which the team has moved to lock in the definition with money, not just papers. Before peer review of the underlying work, the researchers have filed the technology under a public benefit corporation, a corporate structure that lets a for-profit entity explicitly serve a stated public mission (University of Minnesota). Public benefit corporations have become the preferred vehicle for synthetic-biology start-ups sitting on technology whose commercial value depends on the public accepting a particular claim about what the product is doing. Owning the word "cell", or at least the word "SpudCell", early lets the project license, publish, and partner without waiting for a field-wide consensus on whether the construct is alive.
That race to define a category is the story that runs underneath the philosophical one. Synthetic biology has spent a decade delivering objects that look increasingly like cells but require increasingly elaborate chemical scaffolding to keep working. Each step narrows the distance between a mixture of defined molecules and a self-sustaining organism, and each step makes the question "is this alive?" a more consequential commercial question, not just an academic one. By filing as a PBC before the science community reaches agreement, Adamala's team is essentially betting that ownership of the technology and the brand will outrun the contested boundary (The Guardian coverage).
What to watch next is three things. First, a peer-reviewed paper laying out the exact chemistry, replication protocol, and plasmid retention statistics, where Adamala's 30 percent figure can be stress-tested against the work at JCVI and other minimal-cell labs. Second, an early read on whether SpudCell's PBC structure attracts partners or draws fire from biosecurity advocates, who argue that selling partly self-replicating chemical systems raises dual-use questions the field has not yet addressed (CNN science coverage). Third, a sharper public answer to a question that today's statements leave open: if SpudCell is not yet alive, what experiment would move it across the line?